Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial Article

Open Access ESI Most Cited Paper Industry Collaboration International Collaboration

cited authors

  • West, Howard Jack; McCleland, Mark; Cappuzzo, Federico; Reck, Martin; Mok, Tony Sk; Jotte, Robert M.; Nishio, Makoto; Kim, Eugene; Morris, Stefanie; Zou, Wei; Shames, David; Das Thakur, Meghna; Shankar, Geetha; Socinski, Mark A.

authors

Publication Date

  • February 1, 2022

webpage

published in

category

keywords

  • biomarkers
  • immunotherapy
  • lung neoplasms
  • programmed cell death 1 receptor
  • tumor
  • tumor biomarkers

volume

  • 10

issue

  • 2